David Kirn, Chief Executive Officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 204,473 shares at $17.27 ($3.9M) on 2023-12-15, disclosed to the SEC on 2024-01-08.
Scheduled sale ($3.9M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.27 | 28,632 | $494K | 12.6% |
| 2 | $17.27 | 28,632 | $494K | 12.6% |
| 3 | $18.13 | 4,702 | $85K | 2.2% |
| 4 | $18.13 | 4,702 | $85K | 2.2% |
| 5 | $20.31 | 40,732 | $827K | 21.1% |
| 6 | $20.31 | 40,732 |
| $827K |
| 21.1% |
| 7 | $19.56 | 28,104 | $550K | 14.0% |
| 8 | $19.56 | 28,104 | $550K | 14.0% |
| 9 | $20.11 | 133 | $3K | 0.1% |
| Total | $19.15 avg | 204,473 | $3.9M | 100% |
| Filing → |
| FDMT | SELL | 2026-08-21 | $1.1M | — | Filing → |
| FDMT | SELL | 2026-08-05 | $275K | — | Filing → |
| FDMT | SELL | 2026-08-04 | $125K | — | Filing → |